Genetically engineered T lymphocytes have emerged as """"""""off-the-shelf"""""""" serial killers capable of recognizing and eradicating solid and hematological cancers in vivo. T cells expressing chimeric antigen receptors (CARs) have the capacity of coupling MHC-unrestricted antibody-based antigen specificity with TCR-z and costimulatory signaling domains for antigen triggered T cell proliferation, engraftment and anti-tumor activity. Still, conventional gene therapy strategies developed for used in cell-based therapy for cancer are uniformly fixed in their antigen specificity, meaning only patients fortunat enough to have the prescribed antigen expressed on the surface of their cancer cells have the potential to experience meaningful benefit and may have limited efficacy in tumors with heterogeneous tumor-associated antigen expression. The cellular therapy field remains hindered by the inability to successfully develop the technology to deliver a flexible platform for the generation of highly personalized antigen-specific T cells with robust effector function and enhanced survival properties that can be widely applied for the treatment of the majority of patients with advanced disease. The capacity to develop a universal and flexible platform for the generation of non-MHC-restricted antigen-specific T cells has clear and significant clinical implications for adoptive immunotherapy of cancer and chronic viral infection. We build upon strong proof-of-concept results to test the central hypothesis that CAR-like therapy can be dramatically improved and widely applied to target multiple and diverse antigens either simultaneously or sequentially through innovative platform re-development. This extends upon NIH investment under the NIH R21 Exploratory/Developmental Bioengineering Research Grant mechanism, where the feasibility study scored in the 1% percentile and was noted for its innovative nature and strong potential for in vitro and clinical applications. Having now successfully established feasibility for universal immune receptors and identified opportunities for platform improvement, we are now well-positioned to extend these promising studies. Here, we unite scientific expertise in advanced antibody development and T cell-based gene engineering to propose 1) to optimize universal immune receptor construction for increased antibody intermediate binding;2) to develop pre-therapeutic antibody-based imaging of TAA to combine with redirected T cell therapy as a predictor of potential for response;and 3) to improve anti-tumor efficacy in vivo through immune receptor re-development and improved tumor penetrance. Successful application of universal immune receptor platform as proposed here is staged to revolutionize CAR-like gene therapy through development of adaptable systems that allow for the first time flexibility in targeted antigen-specificity by redirected T cells and optiized T cell survival and function in vivo.
Innovative personalized approaches that broaden patient accessibility to T cell-based therapy are required to improve the control of advanced cancer and enhance health. In this study, we propose a pioneering approach to overcome the current limitations to engineered T cell therapy through the development of a universal system of T cell-based tumor targeting and killing. The public health benefit of this research will be the development of a highly personalized, """"""""tailor-made"""""""" T cells based platform designed to broaden patient accessibility to effective T cell-based therapy of cancer.
|Lynn, R C; Feng, Y; Schutsky, K et al. (2016) High-affinity FRÎ²-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30:1355-64|
|Smith, Jenessa B; Lanitis, Evripidis; Dangaj, Denarda et al. (2016) Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. Mol Ther 24:1987-1999|
|Lynn, Rachel C; Poussin, Mathilde; Kalota, Anna et al. (2015) Targeting of folate receptor Î² on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 125:3466-76|
|Lynn, Rachel C; Powell Jr, Daniel J (2015) Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. Mol Ther 23:1559-61|
|Maus, Marcela V; Powell Jr, Daniel J (2015) Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity. Cancer J 21:475-9|
|Bowtell, David D; BÃ¶hm, Steffen; Ahmed, Ahmed A et al. (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668-79|
|Schutsky, Keith; Song, D Gang; Lynn, Rachel et al. (2015) Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget 6:28911-28|
|Urbanska, Katarzyna; Stashwick, Caitlin; Poussin, Mathilde et al. (2015) Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer. Cancer Immunol Res 3:1130-7|
|Urbanska, Katarzyna; Powell Jr, Daniel J (2015) Advances and prospects in adoptive cell transfer therapy for ovarian cancer. Immunotherapy 7:473-6|
|Ye, Qunrui; Song, De-Gang; Poussin, Mathilde et al. (2014) CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 20:44-55|
Showing the most recent 10 out of 15 publications